nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—ALB—epilepsy syndrome	0.168	1	CbGaD
Valsartan—ALB—Oxcarbazepine—epilepsy syndrome	0.0637	0.128	CbGbCtD
Valsartan—ALB—Fosphenytoin—epilepsy syndrome	0.0557	0.112	CbGbCtD
Valsartan—ALB—Clonazepam—epilepsy syndrome	0.0504	0.101	CbGbCtD
Valsartan—ALB—Rufinamide—epilepsy syndrome	0.0411	0.0824	CbGbCtD
Valsartan—ALB—Phenytoin—epilepsy syndrome	0.0359	0.072	CbGbCtD
Valsartan—ALB—Propofol—epilepsy syndrome	0.0335	0.0672	CbGbCtD
Valsartan—CYP2C9—Trimethadione—epilepsy syndrome	0.0319	0.0641	CbGbCtD
Valsartan—ALB—Diazepam—epilepsy syndrome	0.0303	0.0609	CbGbCtD
Valsartan—CYP2C9—Fosphenytoin—epilepsy syndrome	0.03	0.0603	CbGbCtD
Valsartan—CYP2C9—Carbamazepine—epilepsy syndrome	0.0216	0.0433	CbGbCtD
Valsartan—CYP2C9—Primidone—epilepsy syndrome	0.0201	0.0404	CbGbCtD
Valsartan—CYP2C9—Phenytoin—epilepsy syndrome	0.0193	0.0388	CbGbCtD
Valsartan—CYP2C9—Propofol—epilepsy syndrome	0.018	0.0362	CbGbCtD
Valsartan—CYP2C9—Phenobarbital—epilepsy syndrome	0.0172	0.0346	CbGbCtD
Valsartan—CYP2C9—Diazepam—epilepsy syndrome	0.0163	0.0328	CbGbCtD
Valsartan—CYP2C9—Valproic Acid—epilepsy syndrome	0.0129	0.0259	CbGbCtD
Valsartan—Irbesartan—JUN—epilepsy syndrome	0.00143	0.458	CrCbGaD
Valsartan—Olmesartan—ABCC2—epilepsy syndrome	0.0007	0.225	CrCbGaD
Valsartan—Irbesartan—CYP2D6—epilepsy syndrome	0.000281	0.09	CrCbGaD
Valsartan—Losartan—CYP2C19—epilepsy syndrome	0.000244	0.0782	CrCbGaD
Valsartan—Candesartan—ABCB1—epilepsy syndrome	0.0002	0.0642	CrCbGaD
Valsartan—Losartan—ALB—epilepsy syndrome	0.000135	0.0434	CrCbGaD
Valsartan—Losartan—ABCB1—epilepsy syndrome	0.000129	0.0414	CrCbGaD
Valsartan—Asthenia—Clonazepam—epilepsy syndrome	9.61e-05	0.000432	CcSEcCtD
Valsartan—Rhinitis—Topiramate—epilepsy syndrome	9.6e-05	0.000432	CcSEcCtD
Valsartan—Back pain—Gabapentin—epilepsy syndrome	9.58e-05	0.000431	CcSEcCtD
Valsartan—Headache—Fosphenytoin—epilepsy syndrome	9.58e-05	0.000431	CcSEcCtD
Valsartan—Haemorrhage—Topiramate—epilepsy syndrome	9.58e-05	0.000431	CcSEcCtD
Valsartan—Hepatitis—Topiramate—epilepsy syndrome	9.58e-05	0.000431	CcSEcCtD
Valsartan—Nervous system disorder—Valproic Acid—epilepsy syndrome	9.57e-05	0.00043	CcSEcCtD
Valsartan—Thrombocytopenia—Valproic Acid—epilepsy syndrome	9.55e-05	0.00043	CcSEcCtD
Valsartan—Palpitations—Pregabalin—epilepsy syndrome	9.55e-05	0.00043	CcSEcCtD
Valsartan—Asthenia—Phenytoin—epilepsy syndrome	9.55e-05	0.00043	CcSEcCtD
Valsartan—Nausea—Midazolam—epilepsy syndrome	9.53e-05	0.000429	CcSEcCtD
Valsartan—Muscle spasms—Gabapentin—epilepsy syndrome	9.53e-05	0.000429	CcSEcCtD
Valsartan—Diarrhoea—Zonisamide—epilepsy syndrome	9.51e-05	0.000428	CcSEcCtD
Valsartan—Pharyngitis—Topiramate—epilepsy syndrome	9.5e-05	0.000428	CcSEcCtD
Valsartan—Loss of consciousness—Pregabalin—epilepsy syndrome	9.5e-05	0.000427	CcSEcCtD
Valsartan—Asthenia—Oxcarbazepine—epilepsy syndrome	9.5e-05	0.000427	CcSEcCtD
Valsartan—Pruritus—Clonazepam—epilepsy syndrome	9.48e-05	0.000426	CcSEcCtD
Valsartan—Vomiting—Vigabatrin—epilepsy syndrome	9.47e-05	0.000426	CcSEcCtD
Valsartan—Skin disorder—Valproic Acid—epilepsy syndrome	9.47e-05	0.000426	CcSEcCtD
Valsartan—Urinary tract disorder—Topiramate—epilepsy syndrome	9.46e-05	0.000426	CcSEcCtD
Valsartan—Cough—Pregabalin—epilepsy syndrome	9.43e-05	0.000424	CcSEcCtD
Valsartan—Pruritus—Phenytoin—epilepsy syndrome	9.41e-05	0.000424	CcSEcCtD
Valsartan—Connective tissue disorder—Topiramate—epilepsy syndrome	9.41e-05	0.000423	CcSEcCtD
Valsartan—Nausea—Levetiracetam—epilepsy syndrome	9.41e-05	0.000423	CcSEcCtD
Valsartan—Rash—Vigabatrin—epilepsy syndrome	9.4e-05	0.000423	CcSEcCtD
Valsartan—Dizziness—Felbamate—epilepsy syndrome	9.39e-05	0.000423	CcSEcCtD
Valsartan—Dermatitis—Vigabatrin—epilepsy syndrome	9.39e-05	0.000422	CcSEcCtD
Valsartan—Urethral disorder—Topiramate—epilepsy syndrome	9.39e-05	0.000422	CcSEcCtD
Valsartan—Pruritus—Oxcarbazepine—epilepsy syndrome	9.36e-05	0.000421	CcSEcCtD
Valsartan—Hypersensitivity—Carbamazepine—epilepsy syndrome	9.36e-05	0.000421	CcSEcCtD
Valsartan—Vision blurred—Gabapentin—epilepsy syndrome	9.34e-05	0.00042	CcSEcCtD
Valsartan—Headache—Vigabatrin—epilepsy syndrome	9.34e-05	0.00042	CcSEcCtD
Valsartan—Vomiting—Diazepam—epilepsy syndrome	9.33e-05	0.00042	CcSEcCtD
Valsartan—Anorexia—Valproic Acid—epilepsy syndrome	9.3e-05	0.000418	CcSEcCtD
Valsartan—Rash—Diazepam—epilepsy syndrome	9.25e-05	0.000416	CcSEcCtD
Valsartan—Dermatitis—Diazepam—epilepsy syndrome	9.24e-05	0.000416	CcSEcCtD
Valsartan—Myalgia—Pregabalin—epilepsy syndrome	9.2e-05	0.000414	CcSEcCtD
Valsartan—Chest pain—Pregabalin—epilepsy syndrome	9.2e-05	0.000414	CcSEcCtD
Valsartan—Arthralgia—Pregabalin—epilepsy syndrome	9.2e-05	0.000414	CcSEcCtD
Valsartan—Dizziness—Zonisamide—epilepsy syndrome	9.19e-05	0.000414	CcSEcCtD
Valsartan—Headache—Diazepam—epilepsy syndrome	9.19e-05	0.000414	CcSEcCtD
Valsartan—Anxiety—Pregabalin—epilepsy syndrome	9.17e-05	0.000412	CcSEcCtD
Valsartan—Diarrhoea—Clonazepam—epilepsy syndrome	9.17e-05	0.000412	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	9.14e-05	0.000411	CcSEcCtD
Valsartan—Hypotension—Valproic Acid—epilepsy syndrome	9.11e-05	0.00041	CcSEcCtD
Valsartan—Asthenia—Carbamazepine—epilepsy syndrome	9.11e-05	0.00041	CcSEcCtD
Valsartan—Diarrhoea—Phenytoin—epilepsy syndrome	9.1e-05	0.00041	CcSEcCtD
Valsartan—Nausea—Fosphenytoin—epilepsy syndrome	9.08e-05	0.000409	CcSEcCtD
Valsartan—Diarrhoea—Oxcarbazepine—epilepsy syndrome	9.06e-05	0.000407	CcSEcCtD
Valsartan—Angioedema—Gabapentin—epilepsy syndrome	9.05e-05	0.000407	CcSEcCtD
Valsartan—Hypersensitivity—Lamotrigine—epilepsy syndrome	9.04e-05	0.000407	CcSEcCtD
Valsartan—Vomiting—Felbamate—epilepsy syndrome	9.03e-05	0.000406	CcSEcCtD
Valsartan—Dry mouth—Pregabalin—epilepsy syndrome	9e-05	0.000405	CcSEcCtD
Valsartan—Pruritus—Carbamazepine—epilepsy syndrome	8.99e-05	0.000404	CcSEcCtD
Valsartan—Rash—Felbamate—epilepsy syndrome	8.95e-05	0.000403	CcSEcCtD
Valsartan—Dermatitis—Felbamate—epilepsy syndrome	8.94e-05	0.000402	CcSEcCtD
Valsartan—Vertigo—Gabapentin—epilepsy syndrome	8.9e-05	0.000401	CcSEcCtD
Valsartan—Headache—Felbamate—epilepsy syndrome	8.9e-05	0.0004	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	8.89e-05	0.0004	CcSEcCtD
Valsartan—Cardiac disorder—Topiramate—epilepsy syndrome	8.89e-05	0.0004	CcSEcCtD
Valsartan—Syncope—Gabapentin—epilepsy syndrome	8.89e-05	0.0004	CcSEcCtD
Valsartan—Dizziness—Clonazepam—epilepsy syndrome	8.86e-05	0.000399	CcSEcCtD
Valsartan—Nausea—Vigabatrin—epilepsy syndrome	8.85e-05	0.000398	CcSEcCtD
Valsartan—Vomiting—Zonisamide—epilepsy syndrome	8.84e-05	0.000398	CcSEcCtD
Valsartan—Insomnia—Valproic Acid—epilepsy syndrome	8.82e-05	0.000397	CcSEcCtD
Valsartan—Oedema—Pregabalin—epilepsy syndrome	8.82e-05	0.000397	CcSEcCtD
Valsartan—Anaphylactic shock—Pregabalin—epilepsy syndrome	8.82e-05	0.000397	CcSEcCtD
Valsartan—Asthenia—Lamotrigine—epilepsy syndrome	8.81e-05	0.000396	CcSEcCtD
Valsartan—Dizziness—Phenytoin—epilepsy syndrome	8.8e-05	0.000396	CcSEcCtD
Valsartan—Rash—Zonisamide—epilepsy syndrome	8.76e-05	0.000394	CcSEcCtD
Valsartan—Infection—Pregabalin—epilepsy syndrome	8.76e-05	0.000394	CcSEcCtD
Valsartan—Paraesthesia—Valproic Acid—epilepsy syndrome	8.76e-05	0.000394	CcSEcCtD
Valsartan—Palpitations—Gabapentin—epilepsy syndrome	8.76e-05	0.000394	CcSEcCtD
Valsartan—Dermatitis—Zonisamide—epilepsy syndrome	8.76e-05	0.000394	CcSEcCtD
Valsartan—Dizziness—Oxcarbazepine—epilepsy syndrome	8.75e-05	0.000394	CcSEcCtD
Valsartan—Nausea—Diazepam—epilepsy syndrome	8.71e-05	0.000392	CcSEcCtD
Valsartan—Loss of consciousness—Gabapentin—epilepsy syndrome	8.71e-05	0.000392	CcSEcCtD
Valsartan—Headache—Zonisamide—epilepsy syndrome	8.71e-05	0.000392	CcSEcCtD
Valsartan—Dyspnoea—Valproic Acid—epilepsy syndrome	8.7e-05	0.000391	CcSEcCtD
Valsartan—Diarrhoea—Carbamazepine—epilepsy syndrome	8.69e-05	0.000391	CcSEcCtD
Valsartan—Angiopathy—Topiramate—epilepsy syndrome	8.69e-05	0.000391	CcSEcCtD
Valsartan—Pruritus—Lamotrigine—epilepsy syndrome	8.68e-05	0.000391	CcSEcCtD
Valsartan—Shock—Pregabalin—epilepsy syndrome	8.68e-05	0.00039	CcSEcCtD
Valsartan—Somnolence—Valproic Acid—epilepsy syndrome	8.67e-05	0.00039	CcSEcCtD
Valsartan—Immune system disorder—Topiramate—epilepsy syndrome	8.65e-05	0.000389	CcSEcCtD
Valsartan—Nervous system disorder—Pregabalin—epilepsy syndrome	8.65e-05	0.000389	CcSEcCtD
Valsartan—Cough—Gabapentin—epilepsy syndrome	8.65e-05	0.000389	CcSEcCtD
Valsartan—Thrombocytopenia—Pregabalin—epilepsy syndrome	8.63e-05	0.000389	CcSEcCtD
Valsartan—Mediastinal disorder—Topiramate—epilepsy syndrome	8.63e-05	0.000388	CcSEcCtD
Valsartan—Dyspepsia—Valproic Acid—epilepsy syndrome	8.59e-05	0.000386	CcSEcCtD
Valsartan—Skin disorder—Pregabalin—epilepsy syndrome	8.57e-05	0.000385	CcSEcCtD
Valsartan—Vomiting—Clonazepam—epilepsy syndrome	8.52e-05	0.000383	CcSEcCtD
Valsartan—Decreased appetite—Valproic Acid—epilepsy syndrome	8.48e-05	0.000382	CcSEcCtD
Valsartan—Alopecia—Topiramate—epilepsy syndrome	8.46e-05	0.000381	CcSEcCtD
Valsartan—Vomiting—Phenytoin—epilepsy syndrome	8.46e-05	0.000381	CcSEcCtD
Valsartan—Rash—Clonazepam—epilepsy syndrome	8.45e-05	0.00038	CcSEcCtD
Valsartan—Dermatitis—Clonazepam—epilepsy syndrome	8.44e-05	0.00038	CcSEcCtD
Valsartan—Myalgia—Gabapentin—epilepsy syndrome	8.44e-05	0.00038	CcSEcCtD
Valsartan—Chest pain—Gabapentin—epilepsy syndrome	8.44e-05	0.00038	CcSEcCtD
Valsartan—Arthralgia—Gabapentin—epilepsy syndrome	8.44e-05	0.00038	CcSEcCtD
Valsartan—Nausea—Felbamate—epilepsy syndrome	8.43e-05	0.00038	CcSEcCtD
Valsartan—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	8.42e-05	0.000379	CcSEcCtD
Valsartan—Vomiting—Oxcarbazepine—epilepsy syndrome	8.42e-05	0.000379	CcSEcCtD
Valsartan—Fatigue—Valproic Acid—epilepsy syndrome	8.41e-05	0.000378	CcSEcCtD
Valsartan—Anxiety—Gabapentin—epilepsy syndrome	8.41e-05	0.000378	CcSEcCtD
Valsartan—Anorexia—Pregabalin—epilepsy syndrome	8.41e-05	0.000378	CcSEcCtD
Valsartan—Dizziness—Carbamazepine—epilepsy syndrome	8.4e-05	0.000378	CcSEcCtD
Valsartan—Diarrhoea—Lamotrigine—epilepsy syndrome	8.4e-05	0.000378	CcSEcCtD
Valsartan—Headache—Clonazepam—epilepsy syndrome	8.39e-05	0.000378	CcSEcCtD
Valsartan—Rash—Phenytoin—epilepsy syndrome	8.39e-05	0.000378	CcSEcCtD
Valsartan—Mental disorder—Topiramate—epilepsy syndrome	8.39e-05	0.000377	CcSEcCtD
Valsartan—Dermatitis—Phenytoin—epilepsy syndrome	8.38e-05	0.000377	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	8.38e-05	0.000377	CcSEcCtD
Valsartan—Rash—Oxcarbazepine—epilepsy syndrome	8.35e-05	0.000376	CcSEcCtD
Valsartan—Constipation—Valproic Acid—epilepsy syndrome	8.34e-05	0.000375	CcSEcCtD
Valsartan—Dermatitis—Oxcarbazepine—epilepsy syndrome	8.34e-05	0.000375	CcSEcCtD
Valsartan—Headache—Phenytoin—epilepsy syndrome	8.34e-05	0.000375	CcSEcCtD
Valsartan—Malnutrition—Topiramate—epilepsy syndrome	8.34e-05	0.000375	CcSEcCtD
Valsartan—Headache—Oxcarbazepine—epilepsy syndrome	8.29e-05	0.000373	CcSEcCtD
Valsartan—Nausea—Zonisamide—epilepsy syndrome	8.26e-05	0.000371	CcSEcCtD
Valsartan—Dry mouth—Gabapentin—epilepsy syndrome	8.25e-05	0.000371	CcSEcCtD
Valsartan—Hypotension—Pregabalin—epilepsy syndrome	8.24e-05	0.000371	CcSEcCtD
Valsartan—Flatulence—Topiramate—epilepsy syndrome	8.21e-05	0.00037	CcSEcCtD
Valsartan—Dysgeusia—Topiramate—epilepsy syndrome	8.16e-05	0.000367	CcSEcCtD
Valsartan—Dizziness—Lamotrigine—epilepsy syndrome	8.12e-05	0.000365	CcSEcCtD
Valsartan—Anaphylactic shock—Gabapentin—epilepsy syndrome	8.09e-05	0.000364	CcSEcCtD
Valsartan—Oedema—Gabapentin—epilepsy syndrome	8.09e-05	0.000364	CcSEcCtD
Valsartan—Vomiting—Carbamazepine—epilepsy syndrome	8.08e-05	0.000363	CcSEcCtD
Valsartan—Back pain—Topiramate—epilepsy syndrome	8.06e-05	0.000363	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	8.03e-05	0.000362	CcSEcCtD
Valsartan—Infection—Gabapentin—epilepsy syndrome	8.03e-05	0.000361	CcSEcCtD
Valsartan—Muscle spasms—Topiramate—epilepsy syndrome	8.01e-05	0.000361	CcSEcCtD
Valsartan—Rash—Carbamazepine—epilepsy syndrome	8.01e-05	0.00036	CcSEcCtD
Valsartan—Dermatitis—Carbamazepine—epilepsy syndrome	8e-05	0.00036	CcSEcCtD
Valsartan—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	7.98e-05	0.000359	CcSEcCtD
Valsartan—Insomnia—Pregabalin—epilepsy syndrome	7.98e-05	0.000359	CcSEcCtD
Valsartan—Nausea—Clonazepam—epilepsy syndrome	7.96e-05	0.000358	CcSEcCtD
Valsartan—Headache—Carbamazepine—epilepsy syndrome	7.96e-05	0.000358	CcSEcCtD
Valsartan—Shock—Gabapentin—epilepsy syndrome	7.96e-05	0.000358	CcSEcCtD
Valsartan—Nervous system disorder—Gabapentin—epilepsy syndrome	7.93e-05	0.000357	CcSEcCtD
Valsartan—Paraesthesia—Pregabalin—epilepsy syndrome	7.92e-05	0.000356	CcSEcCtD
Valsartan—Thrombocytopenia—Gabapentin—epilepsy syndrome	7.92e-05	0.000356	CcSEcCtD
Valsartan—Nausea—Phenytoin—epilepsy syndrome	7.9e-05	0.000356	CcSEcCtD
Valsartan—Dyspnoea—Pregabalin—epilepsy syndrome	7.86e-05	0.000354	CcSEcCtD
Valsartan—Nausea—Oxcarbazepine—epilepsy syndrome	7.86e-05	0.000354	CcSEcCtD
Valsartan—Vision blurred—Topiramate—epilepsy syndrome	7.86e-05	0.000353	CcSEcCtD
Valsartan—Skin disorder—Gabapentin—epilepsy syndrome	7.85e-05	0.000353	CcSEcCtD
Valsartan—Somnolence—Pregabalin—epilepsy syndrome	7.84e-05	0.000353	CcSEcCtD
Valsartan—Vomiting—Lamotrigine—epilepsy syndrome	7.8e-05	0.000351	CcSEcCtD
Valsartan—Urticaria—Valproic Acid—epilepsy syndrome	7.75e-05	0.000349	CcSEcCtD
Valsartan—Rash—Lamotrigine—epilepsy syndrome	7.74e-05	0.000348	CcSEcCtD
Valsartan—Dermatitis—Lamotrigine—epilepsy syndrome	7.73e-05	0.000348	CcSEcCtD
Valsartan—Abdominal pain—Valproic Acid—epilepsy syndrome	7.71e-05	0.000347	CcSEcCtD
Valsartan—Anorexia—Gabapentin—epilepsy syndrome	7.71e-05	0.000347	CcSEcCtD
Valsartan—Headache—Lamotrigine—epilepsy syndrome	7.69e-05	0.000346	CcSEcCtD
Valsartan—Decreased appetite—Pregabalin—epilepsy syndrome	7.67e-05	0.000345	CcSEcCtD
Valsartan—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	7.61e-05	0.000343	CcSEcCtD
Valsartan—Fatigue—Pregabalin—epilepsy syndrome	7.6e-05	0.000342	CcSEcCtD
Valsartan—Hypotension—Gabapentin—epilepsy syndrome	7.56e-05	0.00034	CcSEcCtD
Valsartan—Nausea—Carbamazepine—epilepsy syndrome	7.54e-05	0.000339	CcSEcCtD
Valsartan—Constipation—Pregabalin—epilepsy syndrome	7.54e-05	0.000339	CcSEcCtD
Valsartan—Vertigo—Topiramate—epilepsy syndrome	7.49e-05	0.000337	CcSEcCtD
Valsartan—Syncope—Topiramate—epilepsy syndrome	7.48e-05	0.000336	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	7.37e-05	0.000331	CcSEcCtD
Valsartan—Palpitations—Topiramate—epilepsy syndrome	7.37e-05	0.000331	CcSEcCtD
Valsartan—Loss of consciousness—Topiramate—epilepsy syndrome	7.33e-05	0.00033	CcSEcCtD
Valsartan—Insomnia—Gabapentin—epilepsy syndrome	7.31e-05	0.000329	CcSEcCtD
Valsartan—Nausea—Lamotrigine—epilepsy syndrome	7.29e-05	0.000328	CcSEcCtD
Valsartan—Cough—Topiramate—epilepsy syndrome	7.27e-05	0.000327	CcSEcCtD
Valsartan—Paraesthesia—Gabapentin—epilepsy syndrome	7.26e-05	0.000327	CcSEcCtD
Valsartan—Gastrointestinal pain—Pregabalin—epilepsy syndrome	7.21e-05	0.000324	CcSEcCtD
Valsartan—Dyspnoea—Gabapentin—epilepsy syndrome	7.21e-05	0.000324	CcSEcCtD
Valsartan—Somnolence—Gabapentin—epilepsy syndrome	7.19e-05	0.000323	CcSEcCtD
Valsartan—Hypersensitivity—Valproic Acid—epilepsy syndrome	7.19e-05	0.000323	CcSEcCtD
Valsartan—Dyspepsia—Gabapentin—epilepsy syndrome	7.12e-05	0.00032	CcSEcCtD
Valsartan—Arthralgia—Topiramate—epilepsy syndrome	7.1e-05	0.000319	CcSEcCtD
Valsartan—Myalgia—Topiramate—epilepsy syndrome	7.1e-05	0.000319	CcSEcCtD
Valsartan—Chest pain—Topiramate—epilepsy syndrome	7.1e-05	0.000319	CcSEcCtD
Valsartan—Anxiety—Topiramate—epilepsy syndrome	7.07e-05	0.000318	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	7.05e-05	0.000317	CcSEcCtD
Valsartan—Decreased appetite—Gabapentin—epilepsy syndrome	7.03e-05	0.000316	CcSEcCtD
Valsartan—Urticaria—Pregabalin—epilepsy syndrome	7.01e-05	0.000315	CcSEcCtD
Valsartan—Asthenia—Valproic Acid—epilepsy syndrome	7e-05	0.000315	CcSEcCtD
Valsartan—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	6.98e-05	0.000314	CcSEcCtD
Valsartan—Fatigue—Gabapentin—epilepsy syndrome	6.97e-05	0.000314	CcSEcCtD
Valsartan—Abdominal pain—Pregabalin—epilepsy syndrome	6.97e-05	0.000314	CcSEcCtD
Valsartan—Dry mouth—Topiramate—epilepsy syndrome	6.94e-05	0.000312	CcSEcCtD
Valsartan—Constipation—Gabapentin—epilepsy syndrome	6.91e-05	0.000311	CcSEcCtD
Valsartan—Pruritus—Valproic Acid—epilepsy syndrome	6.9e-05	0.000311	CcSEcCtD
Valsartan—Oedema—Topiramate—epilepsy syndrome	6.8e-05	0.000306	CcSEcCtD
Valsartan—Infection—Topiramate—epilepsy syndrome	6.76e-05	0.000304	CcSEcCtD
Valsartan—Shock—Topiramate—epilepsy syndrome	6.69e-05	0.000301	CcSEcCtD
Valsartan—Diarrhoea—Valproic Acid—epilepsy syndrome	6.67e-05	0.0003	CcSEcCtD
Valsartan—Nervous system disorder—Topiramate—epilepsy syndrome	6.67e-05	0.0003	CcSEcCtD
Valsartan—Thrombocytopenia—Topiramate—epilepsy syndrome	6.66e-05	0.0003	CcSEcCtD
Valsartan—Gastrointestinal pain—Gabapentin—epilepsy syndrome	6.61e-05	0.000298	CcSEcCtD
Valsartan—Skin disorder—Topiramate—epilepsy syndrome	6.61e-05	0.000297	CcSEcCtD
Valsartan—Hypersensitivity—Pregabalin—epilepsy syndrome	6.5e-05	0.000292	CcSEcCtD
Valsartan—Anorexia—Topiramate—epilepsy syndrome	6.48e-05	0.000292	CcSEcCtD
Valsartan—Dizziness—Valproic Acid—epilepsy syndrome	6.45e-05	0.00029	CcSEcCtD
Valsartan—Urticaria—Gabapentin—epilepsy syndrome	6.42e-05	0.000289	CcSEcCtD
Valsartan—Abdominal pain—Gabapentin—epilepsy syndrome	6.39e-05	0.000288	CcSEcCtD
Valsartan—Hypotension—Topiramate—epilepsy syndrome	6.36e-05	0.000286	CcSEcCtD
Valsartan—Asthenia—Pregabalin—epilepsy syndrome	6.33e-05	0.000285	CcSEcCtD
Valsartan—Pruritus—Pregabalin—epilepsy syndrome	6.24e-05	0.000281	CcSEcCtD
Valsartan—Vomiting—Valproic Acid—epilepsy syndrome	6.2e-05	0.000279	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	6.2e-05	0.000279	CcSEcCtD
Valsartan—Insomnia—Topiramate—epilepsy syndrome	6.15e-05	0.000277	CcSEcCtD
Valsartan—Rash—Valproic Acid—epilepsy syndrome	6.15e-05	0.000277	CcSEcCtD
Valsartan—Dermatitis—Valproic Acid—epilepsy syndrome	6.14e-05	0.000276	CcSEcCtD
Valsartan—Headache—Valproic Acid—epilepsy syndrome	6.11e-05	0.000275	CcSEcCtD
Valsartan—Paraesthesia—Topiramate—epilepsy syndrome	6.11e-05	0.000275	CcSEcCtD
Valsartan—Dyspnoea—Topiramate—epilepsy syndrome	6.07e-05	0.000273	CcSEcCtD
Valsartan—Somnolence—Topiramate—epilepsy syndrome	6.05e-05	0.000272	CcSEcCtD
Valsartan—Diarrhoea—Pregabalin—epilepsy syndrome	6.03e-05	0.000271	CcSEcCtD
Valsartan—Dyspepsia—Topiramate—epilepsy syndrome	5.99e-05	0.000269	CcSEcCtD
Valsartan—Hypersensitivity—Gabapentin—epilepsy syndrome	5.96e-05	0.000268	CcSEcCtD
Valsartan—Decreased appetite—Topiramate—epilepsy syndrome	5.91e-05	0.000266	CcSEcCtD
Valsartan—Gastrointestinal disorder—Topiramate—epilepsy syndrome	5.87e-05	0.000264	CcSEcCtD
Valsartan—Fatigue—Topiramate—epilepsy syndrome	5.87e-05	0.000264	CcSEcCtD
Valsartan—Dizziness—Pregabalin—epilepsy syndrome	5.83e-05	0.000262	CcSEcCtD
Valsartan—Constipation—Topiramate—epilepsy syndrome	5.82e-05	0.000262	CcSEcCtD
Valsartan—Asthenia—Gabapentin—epilepsy syndrome	5.8e-05	0.000261	CcSEcCtD
Valsartan—Nausea—Valproic Acid—epilepsy syndrome	5.79e-05	0.000261	CcSEcCtD
Valsartan—Pruritus—Gabapentin—epilepsy syndrome	5.72e-05	0.000257	CcSEcCtD
Valsartan—Vomiting—Pregabalin—epilepsy syndrome	5.61e-05	0.000252	CcSEcCtD
Valsartan—Gastrointestinal pain—Topiramate—epilepsy syndrome	5.56e-05	0.00025	CcSEcCtD
Valsartan—Rash—Pregabalin—epilepsy syndrome	5.56e-05	0.00025	CcSEcCtD
Valsartan—Dermatitis—Pregabalin—epilepsy syndrome	5.55e-05	0.00025	CcSEcCtD
Valsartan—Diarrhoea—Gabapentin—epilepsy syndrome	5.53e-05	0.000249	CcSEcCtD
Valsartan—Headache—Pregabalin—epilepsy syndrome	5.52e-05	0.000249	CcSEcCtD
Valsartan—Urticaria—Topiramate—epilepsy syndrome	5.4e-05	0.000243	CcSEcCtD
Valsartan—Abdominal pain—Topiramate—epilepsy syndrome	5.38e-05	0.000242	CcSEcCtD
Valsartan—Dizziness—Gabapentin—epilepsy syndrome	5.35e-05	0.000241	CcSEcCtD
Valsartan—Nausea—Pregabalin—epilepsy syndrome	5.24e-05	0.000236	CcSEcCtD
Valsartan—Vomiting—Gabapentin—epilepsy syndrome	5.14e-05	0.000231	CcSEcCtD
Valsartan—Rash—Gabapentin—epilepsy syndrome	5.1e-05	0.000229	CcSEcCtD
Valsartan—Dermatitis—Gabapentin—epilepsy syndrome	5.09e-05	0.000229	CcSEcCtD
Valsartan—Headache—Gabapentin—epilepsy syndrome	5.07e-05	0.000228	CcSEcCtD
Valsartan—Hypersensitivity—Topiramate—epilepsy syndrome	5.01e-05	0.000226	CcSEcCtD
Valsartan—Asthenia—Topiramate—epilepsy syndrome	4.88e-05	0.00022	CcSEcCtD
Valsartan—Pruritus—Topiramate—epilepsy syndrome	4.81e-05	0.000217	CcSEcCtD
Valsartan—Nausea—Gabapentin—epilepsy syndrome	4.8e-05	0.000216	CcSEcCtD
Valsartan—Diarrhoea—Topiramate—epilepsy syndrome	4.65e-05	0.000209	CcSEcCtD
Valsartan—Dizziness—Topiramate—epilepsy syndrome	4.5e-05	0.000202	CcSEcCtD
Valsartan—Vomiting—Topiramate—epilepsy syndrome	4.33e-05	0.000195	CcSEcCtD
Valsartan—Rash—Topiramate—epilepsy syndrome	4.29e-05	0.000193	CcSEcCtD
Valsartan—Dermatitis—Topiramate—epilepsy syndrome	4.29e-05	0.000193	CcSEcCtD
Valsartan—Headache—Topiramate—epilepsy syndrome	4.26e-05	0.000192	CcSEcCtD
Valsartan—Nausea—Topiramate—epilepsy syndrome	4.04e-05	0.000182	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—OXT—epilepsy syndrome	2.12e-05	0.000195	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CRH—epilepsy syndrome	2.12e-05	0.000195	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HSPB1—epilepsy syndrome	2.12e-05	0.000195	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL2—epilepsy syndrome	2.12e-05	0.000195	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL3—epilepsy syndrome	2.12e-05	0.000195	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC6A1—epilepsy syndrome	2.11e-05	0.000194	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ITGA2—epilepsy syndrome	2.11e-05	0.000194	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	2.11e-05	0.000194	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCR5—epilepsy syndrome	2.09e-05	0.000192	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—epilepsy syndrome	2.08e-05	0.000191	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	2.06e-05	0.00019	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	2.06e-05	0.000189	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP2D6—epilepsy syndrome	2.06e-05	0.000189	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—HTR2A—epilepsy syndrome	2.05e-05	0.000188	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—PRKCB—epilepsy syndrome	2.03e-05	0.000187	CbGpPWpGaD
Valsartan—ALB—Metabolism—PFKL—epilepsy syndrome	2.02e-05	0.000186	CbGpPWpGaD
Valsartan—ALB—Metabolism—KCNB1—epilepsy syndrome	2.02e-05	0.000186	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLCO1A2—epilepsy syndrome	2.02e-05	0.000186	CbGpPWpGaD
Valsartan—ALB—Metabolism—CACNA2D2—epilepsy syndrome	2.02e-05	0.000186	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC6A8—epilepsy syndrome	2.02e-05	0.000186	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—EPM2A—epilepsy syndrome	2e-05	0.000184	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NHLRC1—epilepsy syndrome	2e-05	0.000184	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GAMT—epilepsy syndrome	2e-05	0.000184	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PNPO—epilepsy syndrome	2e-05	0.000184	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP2C19—epilepsy syndrome	1.98e-05	0.000182	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PRKCB—epilepsy syndrome	1.98e-05	0.000182	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTK2B—epilepsy syndrome	1.97e-05	0.000181	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TSC1—epilepsy syndrome	1.97e-05	0.000181	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP11A1—epilepsy syndrome	1.97e-05	0.000181	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.96e-05	0.00018	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ADRA2A—epilepsy syndrome	1.96e-05	0.00018	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—BCHE—epilepsy syndrome	1.95e-05	0.000179	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AGT—epilepsy syndrome	1.94e-05	0.000178	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CHRM3—epilepsy syndrome	1.94e-05	0.000178	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—KCNJ11—epilepsy syndrome	1.94e-05	0.000178	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ABCG2—epilepsy syndrome	1.93e-05	0.000177	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NTRK2—epilepsy syndrome	1.92e-05	0.000176	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SST—epilepsy syndrome	1.92e-05	0.000176	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR2—epilepsy syndrome	1.92e-05	0.000176	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—DUSP6—epilepsy syndrome	1.9e-05	0.000175	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ATP2A2—epilepsy syndrome	1.88e-05	0.000173	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADRA2A—epilepsy syndrome	1.88e-05	0.000172	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PLAT—epilepsy syndrome	1.87e-05	0.000172	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—SLC2A1—epilepsy syndrome	1.86e-05	0.000171	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CA4—epilepsy syndrome	1.86e-05	0.000171	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—QDPR—epilepsy syndrome	1.86e-05	0.000171	CbGpPWpGaD
Valsartan—ALB—Hemostasis—ADRA2A—epilepsy syndrome	1.86e-05	0.00017	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—POMC—epilepsy syndrome	1.85e-05	0.00017	CbGpPWpGaD
Valsartan—ALB—Metabolism—ATIC—epilepsy syndrome	1.85e-05	0.00017	CbGpPWpGaD
Valsartan—ALB—Metabolism—NEU1—epilepsy syndrome	1.85e-05	0.00017	CbGpPWpGaD
Valsartan—ALB—Metabolism—UPB1—epilepsy syndrome	1.85e-05	0.00017	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAT—epilepsy syndrome	1.85e-05	0.00017	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PLCB1—epilepsy syndrome	1.84e-05	0.000169	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TH—epilepsy syndrome	1.83e-05	0.000168	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.81e-05	0.000166	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.81e-05	0.000166	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CXCL12—epilepsy syndrome	1.8e-05	0.000166	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BDKRB2—epilepsy syndrome	1.8e-05	0.000166	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—POMC—epilepsy syndrome	1.8e-05	0.000165	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PRKCB—epilepsy syndrome	1.8e-05	0.000165	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—IL6ST—epilepsy syndrome	1.79e-05	0.000164	CbGpPWpGaD
Valsartan—ALB—Metabolism—HSD17B4—epilepsy syndrome	1.78e-05	0.000164	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.77e-05	0.000163	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JUNB—epilepsy syndrome	1.77e-05	0.000163	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CNR1—epilepsy syndrome	1.77e-05	0.000163	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PLCB1—epilepsy syndrome	1.76e-05	0.000162	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—COX3—epilepsy syndrome	1.75e-05	0.00016	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS1—epilepsy syndrome	1.74e-05	0.000159	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HTR7—epilepsy syndrome	1.73e-05	0.000159	CbGpPWpGaD
Valsartan—ALB—Metabolism—GBE1—epilepsy syndrome	1.72e-05	0.000158	CbGpPWpGaD
Valsartan—ALB—Metabolism—PPP1R3C—epilepsy syndrome	1.72e-05	0.000158	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	1.68e-05	0.000154	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HBEGF—epilepsy syndrome	1.68e-05	0.000154	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PFKL—epilepsy syndrome	1.66e-05	0.000152	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CACNA2D2—epilepsy syndrome	1.66e-05	0.000152	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLCO1A2—epilepsy syndrome	1.66e-05	0.000152	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—KCNB1—epilepsy syndrome	1.66e-05	0.000152	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC6A8—epilepsy syndrome	1.66e-05	0.000152	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT3—epilepsy syndrome	1.65e-05	0.000151	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—POMC—epilepsy syndrome	1.64e-05	0.00015	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT3—epilepsy syndrome	1.63e-05	0.000149	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP2C19—epilepsy syndrome	1.62e-05	0.000149	CbGpPWpGaD
Valsartan—ALB—Metabolism—ASAH1—epilepsy syndrome	1.62e-05	0.000149	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—epilepsy syndrome	1.61e-05	0.000148	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—ADAM10—epilepsy syndrome	1.61e-05	0.000148	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAUR—epilepsy syndrome	1.61e-05	0.000148	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—CCL2—epilepsy syndrome	1.6e-05	0.000147	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—PLAT—epilepsy syndrome	1.6e-05	0.000147	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCG2—epilepsy syndrome	1.58e-05	0.000145	CbGpPWpGaD
Valsartan—ALB—Metabolism—STXBP1—epilepsy syndrome	1.57e-05	0.000145	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP2C19—epilepsy syndrome	1.54e-05	0.000142	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALAD—epilepsy syndrome	1.53e-05	0.000141	CbGpPWpGaD
Valsartan—ALB—Metabolism—NT5E—epilepsy syndrome	1.53e-05	0.000141	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP11A1—epilepsy syndrome	1.53e-05	0.000141	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—HMOX1—epilepsy syndrome	1.53e-05	0.000141	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC2A1—epilepsy syndrome	1.53e-05	0.00014	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.52e-05	0.00014	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—S100B—epilepsy syndrome	1.52e-05	0.00014	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—UPB1—epilepsy syndrome	1.52e-05	0.000139	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NEU1—epilepsy syndrome	1.52e-05	0.000139	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ATIC—epilepsy syndrome	1.52e-05	0.000139	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CAT—epilepsy syndrome	1.51e-05	0.000139	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SOCS3—epilepsy syndrome	1.51e-05	0.000138	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDC42—epilepsy syndrome	1.5e-05	0.000138	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CDC42—epilepsy syndrome	1.48e-05	0.000136	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ABCB1—epilepsy syndrome	1.47e-05	0.000135	CbGpPWpGaD
Valsartan—ALB—Metabolism—ALDH7A1—epilepsy syndrome	1.46e-05	0.000134	CbGpPWpGaD
Valsartan—ALB—Metabolism—CACNA1A—epilepsy syndrome	1.46e-05	0.000134	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HSD17B4—epilepsy syndrome	1.46e-05	0.000134	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AVP—epilepsy syndrome	1.45e-05	0.000134	CbGpPWpGaD
Valsartan—ALB—Metabolism—ST3GAL3—epilepsy syndrome	1.43e-05	0.000131	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PPP1R3C—epilepsy syndrome	1.41e-05	0.000129	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GBE1—epilepsy syndrome	1.41e-05	0.000129	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADSL—epilepsy syndrome	1.4e-05	0.000129	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.39e-05	0.000127	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP2D6—epilepsy syndrome	1.38e-05	0.000127	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—epilepsy syndrome	1.38e-05	0.000126	CbGpPWpGaD
Valsartan—ALB—Metabolism—GLUL—epilepsy syndrome	1.38e-05	0.000126	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HES1—epilepsy syndrome	1.37e-05	0.000126	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GPX1—epilepsy syndrome	1.37e-05	0.000125	CbGpPWpGaD
Valsartan—ALB—Metabolism—CACNA1D—epilepsy syndrome	1.35e-05	0.000124	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FYN—epilepsy syndrome	1.34e-05	0.000123	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—H2AFX—epilepsy syndrome	1.33e-05	0.000122	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MEF2C—epilepsy syndrome	1.33e-05	0.000122	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ASAH1—epilepsy syndrome	1.32e-05	0.000122	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FYN—epilepsy syndrome	1.32e-05	0.000121	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.32e-05	0.000121	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ADRA2A—epilepsy syndrome	1.32e-05	0.000121	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—BCHE—epilepsy syndrome	1.31e-05	0.00012	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—STXBP1—epilepsy syndrome	1.29e-05	0.000118	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—YWHAZ—epilepsy syndrome	1.29e-05	0.000118	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NGF—epilepsy syndrome	1.27e-05	0.000117	CbGpPWpGaD
Valsartan—ALB—Hemostasis—YWHAZ—epilepsy syndrome	1.27e-05	0.000117	CbGpPWpGaD
Valsartan—ALB—Metabolism—TXNRD1—epilepsy syndrome	1.26e-05	0.000116	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NT5E—epilepsy syndrome	1.26e-05	0.000115	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALAD—epilepsy syndrome	1.26e-05	0.000115	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—HMOX1—epilepsy syndrome	1.25e-05	0.000115	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—SLC2A1—epilepsy syndrome	1.25e-05	0.000115	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—AVP—epilepsy syndrome	1.24e-05	0.000114	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PLCB1—epilepsy syndrome	1.24e-05	0.000114	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCR5—epilepsy syndrome	1.24e-05	0.000114	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TH—epilepsy syndrome	1.23e-05	0.000113	CbGpPWpGaD
Valsartan—ALB—Metabolism—AQP1—epilepsy syndrome	1.23e-05	0.000113	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.21e-05	0.000111	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HTR2A—epilepsy syndrome	1.21e-05	0.000111	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—ABCB1—epilepsy syndrome	1.2e-05	0.000111	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AGT—epilepsy syndrome	1.2e-05	0.00011	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CACNA1A—epilepsy syndrome	1.2e-05	0.00011	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALDH7A1—epilepsy syndrome	1.2e-05	0.00011	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SRC—epilepsy syndrome	1.19e-05	0.00011	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	1.18e-05	0.000108	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOE—epilepsy syndrome	1.17e-05	0.000108	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ST3GAL3—epilepsy syndrome	1.17e-05	0.000108	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—epilepsy syndrome	1.16e-05	0.000107	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TSC2—epilepsy syndrome	1.15e-05	0.000106	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADSL—epilepsy syndrome	1.15e-05	0.000105	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AGT—epilepsy syndrome	1.15e-05	0.000105	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PLAU—epilepsy syndrome	1.13e-05	0.000104	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GLUL—epilepsy syndrome	1.13e-05	0.000103	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOE—epilepsy syndrome	1.12e-05	0.000103	CbGpPWpGaD
Valsartan—ALB—Metabolism—KCNJ11—epilepsy syndrome	1.11e-05	0.000102	CbGpPWpGaD
Valsartan—ALB—Metabolism—CHRM3—epilepsy syndrome	1.11e-05	0.000102	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CACNA1D—epilepsy syndrome	1.11e-05	0.000101	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—KDR—epilepsy syndrome	1.1e-05	0.000101	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PRKCB—epilepsy syndrome	1.06e-05	9.74e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—IL6ST—epilepsy syndrome	1.06e-05	9.7e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—PRKCB—epilepsy syndrome	1.05e-05	9.62e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS2—epilepsy syndrome	1.04e-05	9.51e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TXNRD1—epilepsy syndrome	1.03e-05	9.49e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	1.03e-05	9.48e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—HMOX1—epilepsy syndrome	1.03e-05	9.45e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAT—epilepsy syndrome	1.01e-05	9.32e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	1.01e-05	9.29e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—POMC—epilepsy syndrome	1.01e-05	9.26e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AQP1—epilepsy syndrome	1e-05	9.22e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCB1—epilepsy syndrome	9.87e-06	9.07e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—POMC—epilepsy syndrome	9.66e-06	8.87e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	9.64e-06	8.85e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CCL2—epilepsy syndrome	9.45e-06	8.68e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ALB—epilepsy syndrome	9.19e-06	8.44e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GPX1—epilepsy syndrome	9.18e-06	8.43e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—KCNJ11—epilepsy syndrome	9.08e-06	8.33e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CHRM3—epilepsy syndrome	9.08e-06	8.33e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCG2—epilepsy syndrome	9.04e-06	8.3e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2C19—epilepsy syndrome	8.81e-06	8.09e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP11A1—epilepsy syndrome	8.75e-06	8.04e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	8.69e-06	7.98e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FGF2—epilepsy syndrome	8.54e-06	7.85e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	8.45e-06	7.76e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	8.28e-06	7.6e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AGT—epilepsy syndrome	8.05e-06	7.39e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—epilepsy syndrome	8.04e-06	7.39e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RELA—epilepsy syndrome	7.93e-06	7.28e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP2D6—epilepsy syndrome	7.9e-06	7.26e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—epilepsy syndrome	7.89e-06	7.24e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MTOR—epilepsy syndrome	7.78e-06	7.14e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ADRA2A—epilepsy syndrome	7.52e-06	6.91e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—BCHE—epilepsy syndrome	7.49e-06	6.88e-05	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	7.42e-06	6.82e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCG2—epilepsy syndrome	7.4e-06	6.79e-05	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—AKT1—epilepsy syndrome	7.22e-06	6.63e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2C19—epilepsy syndrome	7.21e-06	6.62e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	7.17e-06	6.58e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CASP3—epilepsy syndrome	7.15e-06	6.57e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—SLC2A1—epilepsy syndrome	7.15e-06	6.56e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	7.11e-06	6.53e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PLCB1—epilepsy syndrome	7.07e-06	6.49e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—TH—epilepsy syndrome	7.04e-06	6.47e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—JUN—epilepsy syndrome	6.95e-06	6.38e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	6.93e-06	6.37e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—POMC—epilepsy syndrome	6.77e-06	6.22e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—epilepsy syndrome	6.76e-06	6.21e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—AKT1—epilepsy syndrome	6.56e-06	6.02e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	6.49e-06	5.96e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	6.47e-06	5.94e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SRC—epilepsy syndrome	6.23e-06	5.72e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ALB—epilepsy syndrome	6.18e-06	5.67e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SRC—epilepsy syndrome	6.16e-06	5.66e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	6.16e-06	5.65e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—BCHE—epilepsy syndrome	6.13e-06	5.63e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—epilepsy syndrome	6.07e-06	5.57e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—epilepsy syndrome	6e-06	5.51e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—HMOX1—epilepsy syndrome	5.88e-06	5.4e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	5.85e-06	5.37e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAT—epilepsy syndrome	5.8e-06	5.33e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	5.78e-06	5.31e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TH—epilepsy syndrome	5.76e-06	5.29e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	5.67e-06	5.21e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCB1—epilepsy syndrome	5.64e-06	5.18e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—epilepsy syndrome	5.4e-06	4.96e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—GPX1—epilepsy syndrome	5.24e-06	4.82e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	4.81e-06	4.42e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAT—epilepsy syndrome	4.75e-06	4.36e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	4.62e-06	4.24e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AGT—epilepsy syndrome	4.6e-06	4.22e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—epilepsy syndrome	4.51e-06	4.14e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GPX1—epilepsy syndrome	4.29e-06	3.94e-05	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—AKT1—epilepsy syndrome	4.04e-06	3.71e-05	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—AKT1—epilepsy syndrome	3.87e-06	3.56e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—POMC—epilepsy syndrome	3.87e-06	3.55e-05	CbGpPWpGaD
Valsartan—ALB—Hemostasis—AKT1—epilepsy syndrome	3.83e-06	3.51e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AGT—epilepsy syndrome	3.76e-06	3.46e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—epilepsy syndrome	3.69e-06	3.39e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—POMC—epilepsy syndrome	3.17e-06	2.91e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—epilepsy syndrome	3.09e-06	2.84e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ALB—epilepsy syndrome	2.89e-06	2.65e-05	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—AKT1—epilepsy syndrome	2.72e-06	2.49e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	2.53e-06	2.32e-05	CbGpPWpGaD
Valsartan—ALB—Metabolism—AKT1—epilepsy syndrome	1.55e-06	1.42e-05	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—AKT1—epilepsy syndrome	1.27e-06	1.17e-05	CbGpPWpGaD
